Share-based Payment Arrangement, Expense in USD of Gain Therapeutics, Inc. from Q2 2021 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Gain Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense history and change rate from Q2 2021 to Q3 2025.
  • Gain Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $460,005, a 28.7% increase year-over-year.
  • Gain Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $-438,877, a 117% decline year-over-year.
  • Gain Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $190,424, a 94.2% decline from 2023.
  • Gain Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $3,259,026, a 114% increase from 2022.
  • Gain Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $1,526,434, a 81.9% increase from 2021.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Gain Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $-438,877 $460,005 +$102,500 +29% 01 Jul 2025 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $-541,377 $522,019 -$960,881 -65% 01 Apr 2025 30 Jun 2025 10-Q 12 Aug 2025 2025 Q2
Q1 2025 $419,504 $419,504 +$229,080 +120% 01 Jan 2025 31 Mar 2025 10-Q 14 May 2025 2025 Q1
Q4 2024 $190,424 $-1,840,405 -$2,393,506 -433% 01 Oct 2024 31 Dec 2024 10-Q 14 May 2025 2025 Q1
Q3 2024 $2,583,930 $357,505 -$458,496 -56% 01 Jul 2024 30 Sep 2024 10-Q 12 Nov 2025 2025 Q3
Q2 2024 $3,042,426 $1,482,900 +$158,408 +12% 01 Apr 2024 30 Jun 2024 10-Q 12 Aug 2025 2025 Q2
Q1 2024 $2,884,018 $190,424 -$375,008 -66% 01 Jan 2024 31 Mar 2024 10-Q 14 May 2024 2024 Q1
Q4 2023 $3,259,026 $553,101 -$5,591 -1% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $3,264,617 $816,001 +$460,354 +129% 01 Jul 2023 30 Sep 2023 10-Q 14 Nov 2024 2024 Q3
Q2 2023 $2,804,263 $1,324,492 +$1,018,942 +333% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $1,785,321 $565,432 +$258,887 +84% 01 Jan 2023 31 Mar 2023 10-Q 14 May 2024 2024 Q1
Q4 2022 $1,526,434 $558,692 01 Oct 2022 31 Dec 2022 10-K 26 Mar 2024 2023 FY
Q3 2022 $355,647 +$104,822 +42% 01 Jul 2022 30 Sep 2022 10-Q 14 Nov 2023 2023 Q3
Q2 2022 $305,550 +$113,988 +60% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $306,545 01 Jan 2022 31 Mar 2022 10-Q 12 May 2023 2023 Q1
Q3 2021 $250,825 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $191,562 01 Apr 2021 30 Jun 2021 10-Q 08 Aug 2022 2022 Q2

Gain Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $190,424 -$3,068,602 -94% 01 Jan 2024 31 Dec 2024 10-Q 14 May 2025 2025 Q1
2023 $3,259,026 +$1,732,592 +114% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $1,526,434 +$687,063 +82% 01 Jan 2022 31 Dec 2022 10-K 26 Mar 2024 2023 FY
2021 $839,371 01 Jan 2021 31 Dec 2021 10-K 23 Mar 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.